questions and answers (15of28) generic drugs forum – apr. 3-4, 2019
Published 4 years ago • 245 plays • Length 15:46
Download video MP4
Download video MP3
Similar videos
-
27:46
questions and answers (11of28) generic drugs forum – apr. 3-4, 2019
-
10:36
questions and answers (28of28) generic drugs forum – apr. 3-4, 2019
-
23:55
questions and answers (23of28) generic drugs forum – apr. 3-4, 2019
-
33:04
questions and answers (19of28) generic drugs forum – apr. 3-4, 2019
-
3:23
questions and answers (5of28) generic drugs forum – apr. 3-4, 2019
-
42:28
drug master files (dmfs) from an anda perspective (7of28) generic drugs forum – apr. 3-4, 2019
-
14:24
assessment tips (17of28) generic drugs forum – apr. 3-4, 2019
-
25:40
impurity case studies: pharmacology/toxicology (22of28) generic drugs forum – apr. 3-4, 2019
-
16:19
referencing approved drug products in anda submissions (9of28) generic drugs forum – apr. 3-4, 2019
-
38:02
types of fees and q&a (24of28) generic drugs forum – apr. 3-4, 2019
-
27:53
the importance of quality in our medicines (2of28) generic drugs forum – apr. 3-4, 2019
-
23:35
practical tips on ectd (13of28) generic drugs forum – apr. 3-4, 2019
-
20:08
505(b)(2) nda or anda? (10of28) generic drugs forum – apr. 3-4, 2019
-
18:47
challenges in generic drug safety and surveillance (6of27) generic drugs forum 2018
-
21:56
filing and refuse to receive (rtr) (16of28) generic drugs forum – apr. 3-4, 2019
-
23:31
case studies: inadequate bioequivalence studies (18of28) generic drugs forum – apr. 3-4, 2019
-
46:55
stability case studies (20of28) generic drugs forum – apr. 3-4, 2019
-
19:24
anda policy and regulatory considerations prior to filing (12/28) generic drugs forum 2017
-
19:49
pre-anda meeting or controlled correspondence? (4of28) generic drugs forum – apr. 3-4, 2019
Clip.africa.com - Privacy-policy